Methods of Treating and Preventing Renal Cancer using Dimethane Sulfonate Compounds


This invention describes a series of dimethane sulfonate compounds based on NSC 281612 and compositions comprising a pharmaceutically-acceptable carrier and a compound, or a salt, that are suitable for the treatment of renal cancer. The anti-tumor activity of NSC 281612 has been established in vivo against human renal tumor xenografts in mice. Suitable dosing and administration schedules for treatment of renal tumors have also been determined in this study.

Currently only a few small molecule inhibitors are effective in patients with renal cell carcinoma. Approximately 30,000 patients per year are diagnosed with this disease but many of them are untreatable because of intrinsic drug resistance, and efficient drug transport and detoxification mechanisms.



Potential Commercial Applications: Competitive Advantages:
For treatment or prevention of renal cancer.   Have properties expected of some alkylating agents but, unlike conventional alkylating agents, possess specific activity against renal cell carcinoma.


Inventors:
Susan Mertins (NCI)
Susan Bates (NCI)
David Covell (NCI)
Geoffrey Patton (NCI)
Melinda Hollingshead (NCI)
Bahu Rao Vishnuvajjala (NCI)


Intellectual Property:
PCT Application No. PCT/US2005/037152
US Application No. 12/083,583
US Application No. 13/176,129

Collaboration Opportunity:

The National Cancer Institute, Screening Technologies Branch, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize biomarker assays for clinical utility (potential molecular targets have been identified). Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.


Licensing Contact:
Patrick McCue , Ph.D.
NIH Office of Technology Transfer
Email: McCuepat@mail.nih.gov
Phone: 301-496-7057

OTT Reference No: E-249-2005/0

Updated: Nov-01-2012